Novartis expanded its cardiovascular RNA interference (RNAi) pipeline by entering a multi-asset licensing and option agreement with Argo Biopharma worth up to $5.2 billion. The upfront $160 million payment secures rights to discovery-stage siRNA candidates aimed at severe hypertriglyceridemia and mixed dyslipidemia, along with an ongoing Phase II ANGPTL3-targeting candidate. This strategic collaboration reinforces Novartis’ commitment to advancing innovative genetic medicines targeting cardiovascular diseases, which cause approximately one-third of global mortality.